Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

Around the world, progressive parties have come to see tight immigration restrictions as unnecessary, even cruel. What if ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Last year, the Vanguard S&P 500 Growth ETF ranked as the biggest winner among Vanguard's exchange-traded funds (ETFs). That's ...

Novo Nordisk A/S was the biggest leader among large stocks during the session, gaining 5.8%, and DNO ASA gained 5.4%. Carlsberg A/S Series A rounded out the top three leaders on Friday, with shares ...

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...